In this report, the Liver Biopsy Market has been segmented by Type, Indication, End User, and Geography.

Liver Biopsy Market, Segmentation by Type

The Liver Biopsy Market has been segmented by Type into Percutaneous, Transjugular, and Laparoscopic.

Percutaneous Liver Biopsy
The percutaneous liver biopsy remains the most widely adopted technique in the global market. This minimally invasive procedure involves inserting a biopsy needle through the skin, often under imaging guidance like ultrasound, to retrieve a liver tissue sample. Its widespread use is attributed to its cost-effectiveness, ease of use, and short recovery period. Approximately 65% to 70% of all liver biopsies are performed using this method, making it a cornerstone in liver diagnostics.

Transjugular Liver Biopsy
Transjugular liver biopsy is primarily used for patients who are at high risk of bleeding or those with ascites. This technique involves guiding a catheter through the jugular vein into the hepatic vein to collect tissue, significantly reducing the likelihood of complications. Despite being more technically complex and expensive than percutaneous biopsy, it accounts for 20% to 25% of procedures globally. It is particularly valued in critical care and specialized hospital settings.

Laparoscopic Liver Biopsy
The laparoscopic approach is employed when a direct visual inspection of the liver is required during surgery. This method allows surgeons to take targeted tissue samples under direct vision, which is especially useful in detecting focal lesions. Although it is the most invasive and resource-intensive option, it plays a crucial role in oncological and surgical cases. This segment holds a 5% to 10% share of the market, reflecting its specialized nature.

Liver Biopsy Market, Segmentation by Indication

The Liver Biopsy Market has been segmented by Indication into Nonalcoholic Fatty Liver Disease and Chronic Hepatitis B Or C.

Nonalcoholic Fatty Liver Disease (NAFLD)
Nonalcoholic Fatty Liver Disease (NAFLD) has become the primary driver of liver biopsies worldwide. This condition, closely linked to obesity, type 2 diabetes, and metabolic syndrome, includes a range of liver abnormalities from simple fat accumulation to nonalcoholic steatohepatitis (NASH). Liver biopsy remains the most accurate method to assess the severity of liver inflammation and fibrosis in these cases. Around 55% to 60% of all liver biopsies are now conducted for NAFLD, making it the dominant clinical indication.

Chronic Hepatitis B or C
Despite advancements in non-invasive diagnostics, chronic hepatitis B and C continue to necessitate liver biopsies, especially in complex or borderline cases. These viral infections require accurate fibrosis assessment to inform treatment decisions. Although this indication has seen a decline due to effective antiviral therapies, it still accounts for 35% to 40% of liver biopsy procedures globally. Biopsies remain essential when elastography results are inconclusive or when histological confirmation is needed.

Liver Biopsy Market, Segmentation by End User

The Liver Biopsy Market has been segmented by End User into Hospitals & Clinics, and Diagnostic Centers.

Hospitals & Clinics
Hospitals and clinics are the primary end users in the liver biopsy market, accounting for around 70% to 75% of all procedures. These institutions are well-equipped with advanced diagnostic tools, trained personnel, and supportive services like anesthesia and emergency care. Their ability to handle complex cases and provide comprehensive post-procedure care makes them the preferred choice for liver biopsies in both inpatient and outpatient scenarios.

Diagnostic Centers
Diagnostic centers are emerging as a viable alternative for performing liver biopsies, especially in urban regions with a strong focus on ambulatory care. These facilities typically handle lower-risk patients and elective procedures, benefiting from faster service delivery and lower costs. With technological advancements in imaging and biopsy tools, diagnostic centers now account for approximately 25% to 30% of liver biopsy procedures worldwide. Their role is expected to grow as healthcare systems push for decentralization and cost efficiency.

Liver Biopsy Market, Segmentation by Geography

In this report, the Liver Biopsy Market has been segmented by Geography into five regions; North America, Europe, Asia Pacific, Middle East and Africa, and Latin America.

Liver Biopsy Market Share (%), by Geographical Region, 2024

North America
North America leads the liver biopsy market, driven by cutting-edge medical infrastructure, advanced imaging technologies, and a high incidence of liver-related diseases. The region benefits from favorable reimbursement policies and widespread clinical adoption of liver biopsy techniques. With the U.S. accounting for the majority share, North America represents approximately 35% to 40% of the total market.

Europe
Europe follows closely, powered by well-established healthcare systems and a strong emphasis on early detection of chronic diseases. Nations such as Germany, France, and the United Kingdom significantly contribute to the regional demand for liver biopsies. Europe holds an estimated 25% to 28% share of the global market, supported by a steady increase in lifestyle-related liver disorders and government funding for healthcare innovation.

Asia Pacific
The Asia Pacific region is emerging as a major growth engine for the liver biopsy market. Rising prevalence of hepatitis infections, coupled with improvements in healthcare infrastructure, are key growth drivers. Countries like China, India, and Japan are investing heavily in diagnostic technologies. With an estimated 20% to 25% market share, Asia Pacific is positioned for rapid expansion in the near future.

Middle East & Africa and Latin America
Both Middle East & Africa and Latin America are witnessing gradual development in liver biopsy services. These regions currently contribute between 5% to 8% of the global market. As awareness of liver diseases increases and access to healthcare improves, demand for diagnostic procedures such as liver biopsies is expected to grow. Strategic investments and policy support will be crucial in unlocking market potential in these emerging areas.

This report provides an in depth analysis of various factors that impact the dynamics of Liver Biopsy Market. These factors include; Market Drivers, Restraints and Opportunities Analysis.

Drivers, Restraints and Opportunity Analysis

Drivers:

• Increasing liver disease prevalence
• Growing healthcare expenditure

• Rising demand for early diagnosis - The increasing focus on early detection of liver diseases is significantly driving the growth of the liver biopsy market. With a rising incidence of conditions such as hepatitis, non-alcoholic fatty liver disease (NAFLD), cirrhosis, and liver cancer, the demand for accurate diagnostic tools is intensifying. Liver biopsy remains a gold-standard method for obtaining direct insight into liver pathology, enabling clinicians to assess disease stage, monitor progression, and tailor therapeutic strategies. Early diagnosis not only improves patient outcomes but also reduces the long-term burden on healthcare systems.

  Improvements in minimally invasive biopsy techniques, including ultrasound- and CT-guided approaches, have enhanced the safety and precision of the procedure. These advancements have led to increased patient acceptance and broader clinical utilization. As public awareness of liver health continues to grow and screening programs expand, especially in populations at high risk, the demand for reliable and early-stage diagnostic solutions like liver biopsy is expected to rise steadily, reinforcing its critical role in hepatology care.

Restraints:

• Risk of complications from invasive procedures
• High cost of biopsy equipment and tests
• Limited skilled professionals in rural regions

• Patient reluctance due to procedure invasiveness - Patient reluctance stemming from the invasive nature of liver biopsy procedures remains a key restraint in the liver biopsy market. Despite being a highly accurate diagnostic tool, the procedure involves inserting a needle into the liver to collect tissue, which can cause discomfort, anxiety, and fear of complications such as bleeding or infection. This perceived risk often discourages patients from undergoing the test, particularly when alternative non-invasive diagnostic methods, such as imaging or blood-based biomarkers, are available.

  The psychological and physical discomfort associated with liver biopsy can also lead to delays in diagnosis or reduced patient compliance, especially in routine monitoring of chronic liver conditions. This hesitation is more pronounced among elderly patients or those with comorbidities, who may be more sensitive to procedural risks. As a result, the overall utilization of liver biopsy remains limited in certain settings, restraining market growth despite its diagnostic value.

Opportunities:

• Development of minimally invasive biopsy techniques
• Expansion in emerging healthcare infrastructures
• Integration of AI in biopsy interpretation

• Rising clinical trials for liver disease biomarkers - The increasing number of clinical trials focused on liver disease biomarkers is creating promising growth opportunities for the liver biopsy market. As pharmaceutical companies and research institutions intensify efforts to identify and validate biomarkers for early detection, staging, and therapeutic monitoring of liver diseases, liver biopsy remains essential for providing the tissue samples required in these studies. This critical role in biomarker validation reinforces the demand for biopsy procedures in both academic and industry-sponsored research.

  Liver biopsies offer the most direct and comprehensive assessment of liver pathology, making them a valuable standard against which emerging non-invasive tests are compared. With trials exploring biomarkers for conditions such as non-alcoholic steatohepatitis (NASH), hepatitis B and C, liver fibrosis, and hepatocellular carcinoma, biopsy-derived histological data serve as a benchmark for diagnostic accuracy and clinical relevance. This boosts the significance of biopsy procedures in the drug development and approval process.

  Moreover, the expansion of precision medicine is fueling interest in biopsy-based tissue analysis to uncover molecular and genetic signatures that guide individualized treatment approaches. These advancements are increasing the frequency and sophistication of biopsy applications in clinical trial settings, enhancing both the scientific and commercial value of liver biopsy systems. The growing reliance on tissue-level data also supports the integration of biopsy tools with digital pathology and AI-assisted interpretation platforms.

  As investments in liver disease research continue to rise globally, the need for high-quality, tissue-based insights will persist. This positions liver biopsy as a key enabler in advancing biomarker science and accelerating therapeutic innovation, thereby contributing to the sustained growth of the liver biopsy market.

Key players in Liver Biopsy Market include:

• Becton, Dickinson and Company
• MDxHealth
• Veran medical
• Medtronic
• Argon Medical Devices, Inc.
• Mauna Kea Technologies
• Boston Scientific Corporation
• Intact Medical Corp
• C. R. Bard, Inc.
• Leica Biosystems
• Cook Medical
• RI.MOS.
• Hologic, Inc.
• Sterylab
• INRAD Inc.
• Fujifilm Medical Systems

In this report, the profile of each market player provides following information:

• Company Overview and Product Portfolio
• Market Share Analysis
• Key Developments
• Financial Overview
• Strategies
• Company SWOT Analysis